• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      We are proud to present the Haem Streams podcast series discussing hot topics in CLL treatment

       

      Podcast series host

      Your host for the Haem Streams podcast series is Dr Toby Eyre, Consultant Haematologist from Oxford University Hospitals NHS Foundation Trust.

      Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust, specialising in the management of lymphoid malignancies. He is considered a national expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia. 

      His MD doctoral thesis covered early phase trials and biomarker studies in aggressive lymphoid disease. He completed his haematology training in the Oxford Deanery between 2010 and 2017. He is an investigator on a number of national lymphoma and CLL trials and has published over 95 peer-reviewed articles on areas of lymphoma and CLL. He has also presented regularly at national and international conferences.

      He is a core member of the low-grade lymphoma and elderly high-grade lymphoma NCRI clinical studies group and a member of the BSCH guideline writing groups for various lymphoma subtypes. He is a member of the BSH Haemato-Oncology Task Force and the CLL Forum executive committee.

      He also has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education.


      Podcasts

      Episode 1:

      {{currentVideo.name}}
      {{currentVideo.name}}

      {{currentVideo.description}}


      {{currentVideo.long_description}}

       

      Episode 2:

      {{currentVideo.name}}
      {{currentVideo.name}}

      {{currentVideo.description}}


      {{currentVideo.long_description}}

       

      Episode 3:

      {{currentVideo.name}}
      {{currentVideo.name}}

      {{currentVideo.description}}


      {{currentVideo.long_description}}

       

      Episode 4:

      {{currentVideo.name}}
      {{currentVideo.name}}

      {{currentVideo.description}}


      {{currentVideo.long_description}}

       

      BSCH, British Committee for Standards in Haematology; BSH, British Society for Haematology; CLL, chronic lymphocytic leukaemia;
      NCRI, National Cancer Research Institute.

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCCLL-210535. Date of preparation: March 2022.